Interim Report January – September 2024
A fundamental review has been carried out of the company’s strategy
During the past quarter, we have continued to reduce the cost-base for the company, which is partly visible in this quarterly report. Future quarters will show a low cost-base (and negative cash flow), which is something the company can build on.
The company’s current strategy is to focus on the three projects we assess to have the greatest potential for commercial success. These are Nanoimod (where we are looking for a license partner), Nanodotax (where we intend to start an investigator-led study) and NOV202.
Given the current difficulties with raising capital over the market and LIDDS’s current low valuation, it is our strategy to find funding for clinical projects and other further development in other ways. This may involve license deals/partnerships, financing of the subsidiary Noviga Research AB, or targeted issues.
We hope to be able to bring more clarity on these issues to you, our shareholders, in the coming quarters. The board and I are aware that communication to the market has been sparse, but we have as a general strategy to notify the market when we make significant decisions or when we have achieved significant successes or setbacks.
Mats Wiking
CEO and CFO